Please log in to determine if you are eligible to purchase PT Programs.
HLA DISEASE ASSOCIATION-DRUG RISK - DADR1
DADR1
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Analyte Challenges per Shipment Number of Shipments
HLA-A*31:01 3 Two shipments per year
HLA-B*13:01 3
HLA-B*15:02 3
HLA-B*57:01 3
HLA-B*58:01 3

Additional Information

  • This program will challenge the laboratory to accurately identify the presence or absence of alleles associated with a variety of disease states (listed below) and/or the adverse reactions to specific drugs.

    • Carbamazepine-induced Stevens-Johnson syndrome
    • Allopurinol Stevens-Johnson syndrome
    • Hypersensitivity to abacavir
    • Dapsone hypersensitivity

Program Information

  • Three 0.1‑mL specimens, each containing 200 µg/mL of human DNA in media

Shipping Schedule

  • Shipment A: April 9
  • Shipment B: August 20






Customers Who Bought This Item Also Bought
HLA DISEASE ASSOCIATION-DRUG RISK
VIEW DETAILS >